HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on AEON Biopharma (AMEX:AEON) with a maintained price target of $18.
April 17, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AEON Biopharma retains a Buy rating from HC Wainwright & Co. with an unchanged price target of $18.
The reiteration of a Buy rating and maintenance of a $18 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards AEON Biopharma. This endorsement reaffirms the firm's confidence in AEON's potential, likely encouraging both current and potential investors about the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100